{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:06:21Z","timestamp":1791216381969,"version":"4.1.0"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40618-017-0812-x","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T06:48:31Z","timestamp":1515394111000},"page":"881-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Endocrinological aspects of HIV infection"],"prefix":"10.1007","volume":"41","author":[{"given":"F. S.","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chirch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"key":"812_CR1","unstructured":"https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/global-statistics. Accessed 2 Oct 2017"},{"issue":"8","key":"812_CR2","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"C Antiretroviral Therapy Cohort","year":"2017","unstructured":"Antiretroviral Therapy Cohort C (2017) Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 4(8):e349\u2013e356","journal-title":"Lancet HIV"},{"issue":"10","key":"812_CR3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","volume":"165","author":"TT Brown","year":"2005","unstructured":"Brown TT et al (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165(10):1179\u20131184","journal-title":"Arch Intern Med"},{"issue":"6","key":"812_CR4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc07-2013","volume":"31","author":"S Wit De","year":"2008","unstructured":"De Wit S et al (2008) Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:a:D) study. Diabetes Care 31(6):1224\u20131229","journal-title":"Diabetes Care"},{"issue":"9","key":"812_CR5","doi-asserted-by":"crossref","first-page":"e44575","DOI":"10.1371\/journal.pone.0044575","volume":"7","author":"LD Rasmussen","year":"2012","unstructured":"Rasmussen LD et al (2012) Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS ONE 7(9):e44575","journal-title":"PLoS ONE"},{"issue":"2","key":"812_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3851\/IMP1711","volume":"16","author":"S Polsky","year":"2011","unstructured":"Polsky S et al (2011) Incident hyperglycaemia among older adults with or at-risk for HIV infection. Antivir Ther 16(2):181\u2013188","journal-title":"Antivir Ther"},{"issue":"1","key":"812_CR7","doi-asserted-by":"crossref","first-page":"e000304","DOI":"10.1136\/bmjdrc-2016-000304","volume":"5","author":"AC Hernandez-Romieu","year":"2017","unstructured":"Hernandez-Romieu AC et al (2017) Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009\u20132010. BMJ Open Diabetes Res Care 5(1):e000304","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"7","key":"812_CR8","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","volume":"92","author":"VA Triant","year":"2007","unstructured":"Triant VA et al (2007) Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92(7):2506\u20132512","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"812_CR9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10654-012-9707-5","volume":"27","author":"L Galli","year":"2012","unstructured":"Galli L et al (2012) Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol 27(8):657\u2013665","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"812_CR10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/QAI.0b013e3181d0c911","volume":"54","author":"AA Howard","year":"2010","unstructured":"Howard AA et al (2010) The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women\u2019s Interagency HIV Study. J Acquir Immune Defic Syndr 54(2):152\u2013159","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"812_CR11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/QAD.0b013e32832bd7af","volume":"23","author":"AA Butt","year":"2009","unstructured":"Butt AA et al (2009) HIV infection and the risk of diabetes mellitus. AIDS 23(10):1227\u20131234","journal-title":"AIDS"},{"issue":"3","key":"812_CR12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ecl.2014.05.003","volume":"43","author":"C Hadigan","year":"2014","unstructured":"Hadigan C, Kattakuzhy S (2014) Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. Endocrinol Metab Clin North Am 43(3):685\u2013696","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"812_CR13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cyto.2012.01.013","volume":"58","author":"S Veloso","year":"2012","unstructured":"Veloso S et al (2012) Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy. Cytokine 58(2):253\u2013260","journal-title":"Cytokine"},{"issue":"10","key":"812_CR14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/00002030-200307040-00011","volume":"17","author":"C Vigouroux","year":"2003","unstructured":"Vigouroux C et al (2003) Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 17(10):1503\u20131511","journal-title":"AIDS"},{"issue":"6","key":"812_CR15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/08830185.2015.1082178","volume":"35","author":"CS Palmer","year":"2016","unstructured":"Palmer CS et al (2016) Regulators of glucose metabolism in CD4+ and CD8+ T Cells. Int Rev Immunol 35(6):477\u2013488","journal-title":"Int Rev Immunol"},{"issue":"1","key":"812_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hep.20289","volume":"40","author":"AA Butt","year":"2004","unstructured":"Butt AA et al (2004) Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 40(1):115\u2013119","journal-title":"Hepatology"},{"issue":"5","key":"812_CR17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00126334-200308150-00005","volume":"33","author":"SH Mehta","year":"2003","unstructured":"Mehta SH et al (2003) The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 33(5):577\u2013584","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"812_CR18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/QAI.0b013e3182278c09","volume":"58","author":"AK Monroe","year":"2011","unstructured":"Monroe AK et al (2011) Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection. J Acquir Immune Defic Syndr 58(2):173\u2013180","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"812_CR19","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1086\/656630","volume":"51","author":"M Rotger","year":"2010","unstructured":"Rotger M et al (2010) Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis 51(9):1090\u20131098","journal-title":"Clin Infect Dis"},{"issue":"3","key":"812_CR20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.beem.2010.10.017","volume":"25","author":"PW Hruz","year":"2011","unstructured":"Hruz PW (2011) Molecular mechanisms for insulin resistance in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 25(3):459\u2013468","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"13","key":"812_CR21","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","volume":"19","author":"TT Brown","year":"2005","unstructured":"Brown TT et al (2005) Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. Aids 19(13):1375\u20131383","journal-title":"Aids"},{"issue":"2","key":"812_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00002030-200401230-00002","volume":"18","author":"A Cossarizza","year":"2004","unstructured":"Cossarizza A, Moyle G (2004) Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18(2):137\u2013151","journal-title":"AIDS"},{"issue":"5708","key":"812_CR23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1126\/science.1104343","volume":"307","author":"BB Lowell","year":"2005","unstructured":"Lowell BB, Shulman GI (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307(5708):384\u2013387","journal-title":"Science"},{"issue":"1","key":"812_CR24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002030-200501030-00002","volume":"19","author":"GA McComsey","year":"2005","unstructured":"McComsey GA et al (2005) Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 19(1):15\u201323","journal-title":"AIDS"},{"issue":"7","key":"812_CR25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/135965350701200704","volume":"12","author":"N Venhoff","year":"2007","unstructured":"Venhoff N et al (2007) Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 12(7):1075\u20131085","journal-title":"Antivir Ther"},{"issue":"10","key":"812_CR26","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1089\/aid.2011.0327","volume":"28","author":"JA Aberg","year":"2012","unstructured":"Aberg JA et al (2012) Metabolic effects of darunavir\/ritonavir versus atazanavir\/ritonavir in treatment-naive, HIV type 1-infected subjects over 48\u00a0weeks. AIDS Res Hum Retroviruses 28(10):1184\u20131195","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"812_CR27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/15284336.2016.1141468","volume":"17","author":"ET Overton","year":"2016","unstructured":"Overton ET et al (2016) Effects of once-daily darunavir\/ritonavir versus atazanavir\/ritonavir on insulin sensitivity in HIV-infected persons over 48\u00a0weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clin Trials 17(2):72\u201377","journal-title":"HIV Clin Trials"},{"issue":"3","key":"812_CR28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40261-014-0266-2","volume":"35","author":"R Quercia","year":"2015","unstructured":"Quercia R et al (2015) Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig 35(3):211\u2013219","journal-title":"Clin Drug Investig"},{"issue":"1","key":"812_CR29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1753-0407.12345","volume":"8","author":"ZT Bloomgarden","year":"2016","unstructured":"Bloomgarden ZT, Handelsman Y (2016) Approaches to treatment 2: comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. J Diabetes 8(1):4\u20136","journal-title":"J Diabetes"},{"issue":"1","key":"812_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cit757","volume":"58","author":"JA Aberg","year":"2014","unstructured":"Aberg JA et al (2014) Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 58(1):1\u201310","journal-title":"Clin Infect Dis"},{"issue":"9","key":"812_CR31","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc09-0177","volume":"32","author":"PS Kim","year":"2009","unstructured":"Kim PS et al (2009) A1C underestimates glycemia in HIV infection. Diabetes Care 32(9):1591\u20131593","journal-title":"Diabetes Care"},{"issue":"12","key":"812_CR32","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1089\/aid.2006.22.1242","volume":"22","author":"ME Diop","year":"2006","unstructured":"Diop ME et al (2006) Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients. AIDS Res Hum Retrovir 22(12):1242\u20131247","journal-title":"AIDS Res Hum Retrovir"},{"issue":"4","key":"812_CR33","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1086\/376633","volume":"37","author":"PM Polgreen","year":"2003","unstructured":"Polgreen PM, Putz D, Stapleton JT (2003) Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis 37(4):e53\u2013e56","journal-title":"Clin Infect Dis"},{"issue":"4","key":"812_CR34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3851\/IMP1557","volume":"15","author":"MJ Glesby","year":"2010","unstructured":"Glesby MJ et al (2010) Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women\u2019s Interagency HIV Study. Antivir Ther 15(4):571\u2013577","journal-title":"Antivir Ther"},{"issue":"12","key":"812_CR35","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1093\/jac\/dku295","volume":"69","author":"L Slama","year":"2014","unstructured":"Slama L et al (2014) Inaccuracy of haemoglobin A1c among HIV-infected men: effects of CD4 cell count, antiretroviral therapies and haematological parameters. J Antimicrob Chemother 69(12):3360\u20133367","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"812_CR36","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","volume":"55","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55(6):1577\u20131596","journal-title":"Diabetologia"},{"issue":"6","key":"812_CR37","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","volume":"30","author":"ARG Look","year":"2007","unstructured":"Look ARG et al (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30(6):1374\u20131383","journal-title":"Diabetes Care"},{"key":"812_CR38","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed 28 Nov 2016"},{"issue":"12","key":"812_CR39","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1517\/13543784.2013.833604","volume":"22","author":"J Hajjar","year":"2013","unstructured":"Hajjar J, Habra MA, Naing A (2013) Metformin: an old drug with new potential. Expert Opin Investig Drugs 22(12):1511\u20131517","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"812_CR40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1293.2007.00488.x","volume":"8","author":"R Kohli","year":"2007","unstructured":"Kohli R et al (2007) A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 8(7):420\u2013426","journal-title":"HIV Med"},{"key":"812_CR41","unstructured":"https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Tivicay\/pdf\/TIVICAY-PI-PIL.PDF. Accessed 2 Oct 2017"},{"issue":"2","key":"812_CR42","doi-asserted-by":"crossref","first-page":"e0116297","DOI":"10.1371\/journal.pone.0116297","volume":"10","author":"GJ Moyle","year":"2015","unstructured":"Moyle GJ et al (2015) A randomized comparative trial of continued abacavir\/lamivudine plus efavirenz or replacement with efavirenz\/emtricitabine\/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLoS ONE 10(2):e0116297","journal-title":"PLoS ONE"},{"issue":"6","key":"812_CR43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2174\/157016209789973691","volume":"7","author":"B Mothe","year":"2009","unstructured":"Mothe B et al (2009) HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. Curr HIV Res 7(6):597\u2013600","journal-title":"Curr HIV Res"},{"issue":"2","key":"812_CR44","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/CIRCULATIONAHA.107.189622","volume":"118","author":"SK Grinspoon","year":"2008","unstructured":"Grinspoon SK et al (2008) State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV\/AIDS: executive summary. Circulation 118(2):198\u2013210","journal-title":"Circulation"},{"issue":"2","key":"812_CR45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0002-9343(91)80154-E","volume":"90","author":"C Grunfeld","year":"1991","unstructured":"Grunfeld C et al (1991) Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 90(2):154\u2013162","journal-title":"Am J Med"},{"issue":"5","key":"812_CR46","first-page":"1045","volume":"74","author":"C Grunfeld","year":"1992","unstructured":"Grunfeld C et al (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74(5):1045\u20131052","journal-title":"J Clin Endocrinol Metab"},{"key":"812_CR47","first-page":"1","volume":"7","author":"NE Husain","year":"2015","unstructured":"Husain NE, Ahmed MH (2015) Managing dyslipidemia in HIV\/AIDS patients: challenges and solutions. HIV AIDS (Auckl) 7:1\u201310","journal-title":"HIV AIDS (Auckl)"},{"issue":"4","key":"812_CR48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/COH.0000000000000075","volume":"9","author":"M Calvo","year":"2014","unstructured":"Calvo M, Martinez E (2014) Update on metabolic issues in HIV patients. Curr Opin HIV AIDS 9(4):332\u2013339","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"812_CR49","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/jac\/dkv494","volume":"71","author":"L Calza","year":"2016","unstructured":"Calza L et al (2016) Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 71(6):1451\u20131465","journal-title":"J Antimicrob Chemother"},{"key":"812_CR50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1874613601509010023","volume":"9","author":"DB Chastain","year":"2015","unstructured":"Chastain DB, Henderson H, Stover KR (2015) Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J 9:23\u201337","journal-title":"Open AIDS J"},{"issue":"9712","key":"812_CR51","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","volume":"375","author":"JJ Eron","year":"2010","unstructured":"Eron JJ et al (2010) Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 375(9712):396\u2013407","journal-title":"Lancet"},{"issue":"1","key":"812_CR52","first-page":"39","volume":"55","author":"JL Lennox","year":"2010","unstructured":"Lennox JL et al (2010) Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. JAIDS 55(1):39\u201348","journal-title":"JAIDS"},{"issue":"3","key":"812_CR53","first-page":"112","volume":"18","author":"C Grunfeld","year":"2010","unstructured":"Grunfeld C (2010) Dyslipidemia and its treatment in HIV infection. Top HIV Med 18(3):112\u2013118","journal-title":"Top HIV Med"},{"issue":"7","key":"812_CR54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2015.5498","volume":"314","author":"M Mitka","year":"2015","unstructured":"Mitka M (2015) Exploring statins to decrease HIV-related heart disease risk. JAMA 314(7):657\u2013659","journal-title":"JAMA"},{"issue":"18","key":"812_CR55","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.116.021407","volume":"133","author":"M Nayor","year":"2016","unstructured":"Nayor M, Vasan RS (2016) Recent update to the US Cholesterol Treatment Guidelines. A comparison with international guidelines. Circulation 133(18):1795\u20131806","journal-title":"Circulation"},{"issue":"1","key":"812_CR56","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cit665","volume":"58","author":"JA Aberg","year":"2014","unstructured":"Aberg JA et al (2014) Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 58(1):e1\u2013e34","journal-title":"Clin Infect Dis"},{"issue":"1","key":"812_CR57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","volume":"32","author":"KA Lichtenstein","year":"2003","unstructured":"Lichtenstein KA et al (2003) Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 32(1):48\u201356","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"812_CR58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002030-200101260-00013","volume":"15","author":"KV Heath","year":"2001","unstructured":"Heath KV et al (2001) Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment database. AIDS 15(2):231\u2013239","journal-title":"AIDS"},{"issue":"3","key":"812_CR59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00042560-199811010-00015","volume":"19","author":"JC Lo","year":"1998","unstructured":"Lo JC et al (1998) Body shape changes in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 19(3):307\u2013308","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"4","key":"812_CR60","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00002030-200003100-00026","volume":"14","author":"G Leitz","year":"2000","unstructured":"Leitz G, Robinson P (2000) The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen. AIDS 14(4):468\u2013469","journal-title":"AIDS"},{"issue":"4","key":"812_CR61","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00126334-200012010-00004","volume":"25","author":"DC Mynarcik","year":"2000","unstructured":"Mynarcik DC et al (2000) Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 25(4):312\u2013321","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"812_CR62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/QAI.0b013e31816d9ba1","volume":"48","author":"D Wohl","year":"2008","unstructured":"Wohl D et al (2008) The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 48(1):44\u201352","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"812_CR63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/apc.2007.0173","volume":"22","author":"G Guaraldi","year":"2008","unstructured":"Guaraldi G et al (2008) Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS 22(7):577\u2013585","journal-title":"AIDS Patient Care STDS"},{"issue":"7","key":"812_CR64","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/09540120500287051","volume":"18","author":"NR Reynolds","year":"2006","unstructured":"Reynolds NR et al (2006) Balancing disfigurement and fear of disease progression: patient perceptions of HIV body fat redistribution. AIDS Care 18(7):663\u2013673","journal-title":"AIDS Care"},{"issue":"1","key":"812_CR65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00001432-200402000-00005","volume":"17","author":"PC Tien","year":"2004","unstructured":"Tien PC, Grunfeld C (2004) What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 17(1):27\u201332","journal-title":"Curr Opin Infect Dis"},{"issue":"12","key":"812_CR66","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1086\/430379","volume":"40","author":"DL Jacobson","year":"2005","unstructured":"Jacobson DL et al (2005) Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 40(12):1837\u20131845","journal-title":"Clin Infect Dis"},{"issue":"11","key":"812_CR67","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","volume":"15","author":"KA Lichtenstein","year":"2001","unstructured":"Lichtenstein KA et al (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15(11):1389\u20131398","journal-title":"AIDS"},{"issue":"3","key":"812_CR68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","volume":"4","author":"J Miller","year":"2003","unstructured":"Miller J et al (2003) HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 4(3):293\u2013301","journal-title":"HIV Med"},{"issue":"16","key":"812_CR69","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1097\/QAD.0b013e32833e922c","volume":"24","author":"AH Montes","year":"2010","unstructured":"Montes AH et al (2010) The MMP1 (-16071G\/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome. AIDS 24(16):2499\u20132506","journal-title":"AIDS"},{"issue":"1","key":"812_CR70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/QAD.0b013e32833f9d02","volume":"25","author":"T Hulgan","year":"2011","unstructured":"Hulgan T et al (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25(1):37\u201347","journal-title":"AIDS"},{"issue":"3","key":"812_CR71","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00042560-200107010-00004","volume":"27","author":"JR Bogner","year":"2001","unstructured":"Bogner JR et al (2001) Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 27(3):237\u2013244","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"812_CR72","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.qai.0000224974.67962.ce","volume":"42","author":"CL Cherry","year":"2006","unstructured":"Cherry CL et al (2006) Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr 42(4):435\u2013440","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"16","key":"812_CR73","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","volume":"20","author":"GJ Moyle","year":"2006","unstructured":"Moyle GJ et al (2006) A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20(16):2043\u20132050","journal-title":"AIDS"},{"issue":"7","key":"812_CR74","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","volume":"18","author":"A Martin","year":"2004","unstructured":"Martin A et al (2004) Reversibility of lipoatrophy in HIV-infected patients 2\u00a0years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18(7):1029\u20131036","journal-title":"AIDS"},{"issue":"9","key":"812_CR75","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/QAD.0b013e3281c6148d","volume":"21","author":"MR Loutfy","year":"2007","unstructured":"Loutfy MR et al (2007) Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS 21(9):1147\u20131155","journal-title":"AIDS"},{"issue":"3","key":"812_CR76","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1468-1293.2006.00342.x","volume":"7","author":"GJ Moyle","year":"2006","unstructured":"Moyle GJ et al (2006) Long-term safety and efficacy of poly-l-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 7(3):181\u2013185","journal-title":"HIV Med"},{"issue":"4","key":"812_CR77","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2008-1588","volume":"94","author":"K Mulligan","year":"2009","unstructured":"Mulligan K et al (2009) The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 94(4):1137\u20131144","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"812_CR78","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.metabol.2010.10.002","volume":"60","author":"F Magkos","year":"2011","unstructured":"Magkos F et al (2011) Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism 60(7):1045\u20131049","journal-title":"Metabolism"},{"issue":"4","key":"812_CR79","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/QAI.0000000000000001","volume":"64","author":"G Guaraldi","year":"2013","unstructured":"Guaraldi G et al (2013) CD8 T-cell activation is associated with lipodystrophy and visceral fat accumulation in antiretroviral therapy-treated virologically suppressed HIV-infected patients. J Acquir Immune Defic Syndr 64(4):360\u2013366","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"812_CR80","doi-asserted-by":"crossref","first-page":"e1005153","DOI":"10.1371\/journal.ppat.1005153","volume":"11","author":"A Damouche","year":"2015","unstructured":"Damouche A et al (2015) Adipose tissue is a neglected viral reservoir and an inflammatory site during chronic HIV and SIV infection. PLoS Pathog 11(9):e1005153","journal-title":"PLoS Pathog"},{"issue":"2","key":"812_CR81","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/QAI.0b013e31825c3a68","volume":"61","author":"F Vidal","year":"2012","unstructured":"Vidal F et al (2012) Adipogenic\/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden. J Acquir Immune Defic Syndr 61(2):131\u2013137","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"812_CR82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4161\/adip.29852","volume":"4","author":"N Agarwal","year":"2015","unstructured":"Agarwal N, Balasubramanyam A (2015) Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr. Adipocyte 4(1):55\u201359","journal-title":"Adipocyte"},{"issue":"1","key":"812_CR83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00018-015-2061-5","volume":"73","author":"P Gerard","year":"2016","unstructured":"Gerard P (2016) Gut microbiota and obesity. Cell Mol Life Sci 73(1):147\u2013162","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"812_CR84","first-page":"504","volume":"86","author":"P Rietschel","year":"2001","unstructured":"Rietschel P et al (2001) Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 86(2):504\u2013510","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"812_CR85","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","volume":"13","author":"JE Lake","year":"2013","unstructured":"Lake JE, Currier JS (2013) Metabolic disease in HIV infection. Lancet Infect Dis 13(11):964\u2013975","journal-title":"Lancet Infect Dis"},{"issue":"30","key":"812_CR86","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.2174\/138161210793563446","volume":"16","author":"M Caron-Debarle","year":"2010","unstructured":"Caron-Debarle M et al (2010) Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr Pharm Des 16(30):3352\u20133360","journal-title":"Curr Pharm Des"},{"issue":"5","key":"812_CR87","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QAI.0b013e3181142d26","volume":"45","author":"MP Dube","year":"2007","unstructured":"Dube MP et al (2007) Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005S, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 45(5):508\u2013514","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"812_CR88","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","volume":"23","author":"RH Haubrich","year":"2009","unstructured":"Haubrich RH et al (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23(9):1109\u20131118","journal-title":"AIDS"},{"issue":"5","key":"812_CR89","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.molmed.2010.03.002","volume":"16","author":"M Caron-Debarle","year":"2010","unstructured":"Caron-Debarle M et al (2010) HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 16(5):218\u2013229","journal-title":"Trends Mol Med"},{"issue":"7","key":"812_CR90","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw017","volume":"62","author":"GA McComsey","year":"2016","unstructured":"McComsey GA et al (2016) Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260S. Clin Infect Dis 62(7):853\u2013862","journal-title":"Clin Infect Dis"},{"issue":"4","key":"812_CR91","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40261-014-0175-4","volume":"34","author":"GJ Moyle","year":"2014","unstructured":"Moyle GJ et al (2014) Comparison of body composition changes between atazanavir\/ritonavir and lopinavir\/ritonavir each in combination with tenofovir\/emtricitabine in antiretroviral-naive patients with HIV-1 infection. Clin Drug Investig 34(4):287\u2013296","journal-title":"Clin Drug Investig"},{"issue":"10","key":"812_CR92","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1468-1293.2011.00941.x","volume":"12","author":"SM Vrouenraets","year":"2011","unstructured":"Vrouenraets SM et al (2011) Randomized comparison of metabolic and renal effects of saquinavir\/r or atazanavir\/r plus tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients. HIV Med 12(10):620\u2013631","journal-title":"HIV Med"},{"issue":"11","key":"812_CR93","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/QAD.0b013e32834884e6","volume":"25","author":"R Scherzer","year":"2011","unstructured":"Scherzer R et al (2011) Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 25(11):1405\u20131414","journal-title":"AIDS"},{"issue":"11","key":"812_CR94","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/archinte.166.11.1225","volume":"166","author":"SE Dolan","year":"2006","unstructured":"Dolan SE et al (2006) Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Arch Intern Med 166(11):1225\u20131231","journal-title":"Arch Intern Med"},{"issue":"14","key":"812_CR95","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1097\/QAD.0b013e32830a5058","volume":"22","author":"J Falutz","year":"2008","unstructured":"Falutz J et al (2008) Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22(14):1719\u20131728","journal-title":"AIDS"},{"issue":"23","key":"812_CR96","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMoa072375","volume":"357","author":"J Falutz","year":"2007","unstructured":"Falutz J et al (2007) Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357(23):2359\u20132370","journal-title":"N Engl J Med"},{"issue":"9","key":"812_CR97","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2010-0490","volume":"95","author":"J Falutz","year":"2010","unstructured":"Falutz J et al (2010) Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95(9):4291\u20134304","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"812_CR98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrendo.2011.151","volume":"8","author":"TT Brown","year":"2011","unstructured":"Brown TT, Glesby MJ (2011) Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 8(1):11\u201321","journal-title":"Nat Rev Endocrinol"},{"issue":"3 Pt 2","key":"812_CR99","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0002-9343(88)90144-1","volume":"84","author":"AS Dobs","year":"1988","unstructured":"Dobs AS et al (1988) Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 84(3 Pt 2):611\u2013616","journal-title":"Am J Med"},{"issue":"5","key":"812_CR100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/j.1939-4640.1999.tb02562.x","volume":"20","author":"S Arver","year":"1999","unstructured":"Arver S et al (1999) Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss. J Androl 20(5):611\u2013618","journal-title":"J Androl"},{"issue":"2","key":"812_CR101","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.biocel.2008.08.041","volume":"41","author":"JB Dacks","year":"2009","unstructured":"Dacks JB, Peden AA, Field MC (2009) Evolution of specificity in the eukaryotic endomembrane system. Int J Biochem Cell Biol 41(2):330\u2013340","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"812_CR102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s40506-017-0110-3","volume":"9","author":"N Wong","year":"2017","unstructured":"Wong N, Levy M, Stephenson I (2017) Hypogonadism in the HIV-Infected Man. Curr Treat Options Infect Dis 9(1):104\u2013116","journal-title":"Curr Treat Options Infect Dis"},{"issue":"1","key":"812_CR103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4111\/kju.2014.55.1.9","volume":"55","author":"J Ashby","year":"2014","unstructured":"Ashby J, Goldmeier D, Sadeghi-Nejad H (2014) Hypogonadism in human immunodeficiency virus-positive men. Korean J Urol 55(1):9\u201316","journal-title":"Korean J Urol"},{"issue":"12","key":"812_CR104","doi-asserted-by":"crossref","first-page":"e28512","DOI":"10.1371\/journal.pone.0028512","volume":"6","author":"V Rochira","year":"2011","unstructured":"Rochira V et al (2011) Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS ONE 6(12):e28512","journal-title":"PLoS ONE"},{"issue":"3","key":"812_CR105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ecl.2014.06.005","volume":"43","author":"V Rochira","year":"2014","unstructured":"Rochira V, Guaraldi G (2014) Hypogonadism in the HIV-infected man. Endocrinol Metab Clin North Am 43(3):709\u2013730","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"812_CR106","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.mayocp.2016.04.022","volume":"91","author":"M Khera","year":"2016","unstructured":"Khera M et al (2016) Adult-onset hypogonadism. Mayo Clin Proc 91(7):908\u2013926","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"812_CR107","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1111\/j.1532-5415.2009.02494.x","volume":"57","author":"JB Kirk","year":"2009","unstructured":"Kirk JB, Goetz MB (2009) Human immunodeficiency virus in an aging population, a complication of success. J Am Geriatr Soc 57(11):2129\u20132138","journal-title":"J Am Geriatr Soc"},{"issue":"20","key":"812_CR108","doi-asserted-by":"crossref","first-page":"201801","DOI":"10.1103\/PhysRevLett.108.201801","volume":"108","author":"T Aaltonen","year":"2012","unstructured":"Aaltonen T et al (2012) Measurement of Bs0\u2013\u00a0>\u00a0Ds(*)\u00a0+\u00a0Ds(*)- branching ratios. Phys Rev Lett 108(20):201801","journal-title":"Phys Rev Lett"},{"issue":"2","key":"812_CR109","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2337\/dc06-1579","volume":"30","author":"E Selvin","year":"2007","unstructured":"Selvin E et al (2007) Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30(2):234\u2013238","journal-title":"Diabetes Care"},{"issue":"5","key":"812_CR110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/met.2010.0129","volume":"9","author":"JM Cubero","year":"2011","unstructured":"Cubero JM et al (2011) Prevalence of metabolic syndrome among human immunodeficiency virus-infected subjects is widely influenced by the diagnostic criteria. Metab Syndr Relat Disord 9(5):345\u2013351","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"812_CR111","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/dc06-1075","volume":"30","author":"K Samaras","year":"2007","unstructured":"Samaras K et al (2007) Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and (corrected) hypoadiponectinemia. Diabetes Care 30(1):113\u2013119","journal-title":"Diabetes Care"},{"issue":"12","key":"812_CR112","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1086\/498311","volume":"41","author":"RS Klein","year":"2005","unstructured":"Klein RS et al (2005) Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 41(12):1794\u20131803","journal-title":"Clin Infect Dis"},{"issue":"1","key":"812_CR113","doi-asserted-by":"crossref","first-page":"E138","DOI":"10.1152\/ajpendo.00426.2001","volume":"283","author":"R Roubenoff","year":"2002","unstructured":"Roubenoff R et al (2002) Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab 283(1):E138\u2013E145","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"812_CR114","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/andr.310","volume":"3","author":"V Rochira","year":"2015","unstructured":"Rochira V et al (2015) Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study. Andrology 3(2):298\u2013308","journal-title":"Andrology"},{"issue":"4","key":"812_CR115","first-page":"237","volume":"9","author":"J Collazos","year":"2007","unstructured":"Collazos J (2007) Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Rev 9(4):237\u2013245","journal-title":"AIDS Rev"},{"issue":"6","key":"812_CR116","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","volume":"95","author":"S Bhasin","year":"2010","unstructured":"Bhasin S et al (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95(6):2536\u20132559","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"812_CR117","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1468-1293.2007.00533.x","volume":"9","author":"N Clumeck","year":"2008","unstructured":"Clumeck N et al (2008) European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 9(2):65\u201371","journal-title":"HIV Med"},{"issue":"2","key":"812_CR118","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1210\/jc.2006-1864","volume":"92","author":"W Rosner","year":"2007","unstructured":"Rosner W et al (2007) Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92(2):405\u2013413","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 5","key":"812_CR119","first-page":"389","volume":"43","author":"CK Ho","year":"2006","unstructured":"Ho CK et al (2006) Calculated free testosterone in men: comparison of four equations and with free androgen index. Ann Clin Biochem 43(Pt 5):389\u2013397","journal-title":"Ann Clin Biochem"},{"issue":"11","key":"812_CR120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/aje\/kwi324","volume":"162","author":"AM Mondul","year":"2005","unstructured":"Mondul AM et al (2005) Age at natural menopause and cause-specific mortality. Am J Epidemiol 162(11):1089\u20131097","journal-title":"Am J Epidemiol"},{"issue":"9","key":"812_CR121","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/GME.0b013e318282aa57","volume":"20","author":"R Kanapathipillai","year":"2013","unstructured":"Kanapathipillai R, Hickey M, Giles M (2013) Human immunodeficiency virus and menopause. Menopause 20(9):983\u2013990","journal-title":"Menopause"},{"issue":"10","key":"812_CR122","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1086\/497270","volume":"41","author":"EE Schoenbaum","year":"2005","unstructured":"Schoenbaum EE et al (2005) HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 41(10):1517\u20131524","journal-title":"Clin Infect Dis"},{"issue":"11","key":"812_CR123","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1089\/apc.2005.19.703","volume":"19","author":"LE Fantry","year":"2005","unstructured":"Fantry LE et al (2005) Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDS 19(11):703\u2013711","journal-title":"AIDS Patient Care STDS"},{"issue":"3","key":"812_CR124","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/01.GME.0000141981.88782.38","volume":"12","author":"SA Miller","year":"2005","unstructured":"Miller SA et al (2005) Menopause symptoms in HIV-infected and drug-using women. Menopause 12(3):348\u2013356","journal-title":"Menopause"},{"issue":"17","key":"812_CR125","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","volume":"20","author":"TT Brown","year":"2006","unstructured":"Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20(17):2165\u20132174","journal-title":"AIDS"},{"issue":"8","key":"812_CR126","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1086\/656412","volume":"51","author":"GA McComsey","year":"2010","unstructured":"McComsey GA et al (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 51(8):937\u2013946","journal-title":"Clin Infect Dis"},{"issue":"9","key":"812_CR127","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","volume":"93","author":"VA Triant","year":"2008","unstructured":"Triant VA et al (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93(9):3499\u20133504","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"812_CR128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/cid\/ciq242","volume":"52","author":"B Young","year":"2011","unstructured":"Young B et al (2011) Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000\u20132006. Clin Infect Dis 52(8):1061\u20131068","journal-title":"Clin Infect Dis"},{"issue":"3","key":"812_CR129","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00198-015-3383-8","volume":"27","author":"D Santi","year":"2016","unstructured":"Santi D et al (2016) Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study. Osteoporos Int 27(3):1103\u20131114","journal-title":"Osteoporos Int"},{"issue":"8","key":"812_CR130","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/cid\/civ010","volume":"60","author":"TT Brown","year":"2015","unstructured":"Brown TT et al (2015) Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis 60(8):1242\u20131251","journal-title":"Clin Infect Dis"},{"issue":"48","key":"812_CR131","doi-asserted-by":"crossref","first-page":"48251","DOI":"10.1074\/jbc.M304676200","volume":"278","author":"JM Fakruddin","year":"2003","unstructured":"Fakruddin JM, Laurence J (2003) HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma\/RANKL cross-talk. J Biol Chem 278(48):48251\u201348258","journal-title":"J Biol Chem"},{"key":"812_CR132","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1479-5876-11-51","volume":"11","author":"L Gazzola","year":"2013","unstructured":"Gazzola L et al (2013) Association between peripheral T-lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med 11:51","journal-title":"J Transl Med"},{"issue":"5","key":"812_CR133","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","volume":"51","author":"TT Brown","year":"2009","unstructured":"Brown TT et al (2009) Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 51(5):554\u2013561","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"812_CR134","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jbspin.2009.10.003","volume":"76","author":"J Paccou","year":"2009","unstructured":"Paccou J et al (2009) Bone loss in patients with HIV infection. Joint Bone Spine 76(6):637\u2013641","journal-title":"Joint Bone Spine"},{"issue":"12","key":"812_CR135","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/jbmr.1988","volume":"28","author":"NM Maalouf","year":"2013","unstructured":"Maalouf NM et al (2013) Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Miner Res 28(12):2577\u20132583","journal-title":"J Bone Miner Res"},{"issue":"4","key":"812_CR136","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2011.01.035","volume":"55","author":"D El-Maouche","year":"2011","unstructured":"El-Maouche D et al (2011) Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV\/HCV co-infection. J Hepatol 55(4):770\u2013776","journal-title":"J Hepatol"},{"issue":"3","key":"812_CR137","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11904-014-0218-8","volume":"11","author":"AR Eckard","year":"2014","unstructured":"Eckard AR, McComsey GA (2014) Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals. Curr HIV\/AIDS Rep 11(3):263\u2013270","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"5","key":"812_CR138","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.25866","volume":"56","author":"V Lo Re","year":"2012","unstructured":"Lo Re V et al (2012) Risk of hip fracture associated with hepatitis C virus infection and hepatitis C\/human immunodeficiency virus coinfection. Hepatology 56(5):1688\u20131698","journal-title":"Hepatology"},{"issue":"9","key":"812_CR139","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1210\/jc.2008-2422","volume":"94","author":"V Gilsanz","year":"2009","unstructured":"Gilsanz V et al (2009) Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab 94(9):3387\u20133393","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"812_CR140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0167-5699(93)90208-3","volume":"14","author":"M Clerici","year":"1993","unstructured":"Clerici M, Shearer GM (1993) A TH1\u2192TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 14(3):107\u2013111","journal-title":"Immunol Today"},{"issue":"4 Suppl 3","key":"812_CR141","doi-asserted-by":"crossref","first-page":"19724","DOI":"10.7448\/IAS.17.4.19724","volume":"17","author":"N Chew","year":"2014","unstructured":"Chew N et al (2014) HIV-1 tat and rev upregulates osteoclast bone resorption. J Int AIDS Soc 17(4 Suppl 3):19724","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"812_CR142","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11154-013-9246-8","volume":"14","author":"A Panayiotopoulos","year":"2013","unstructured":"Panayiotopoulos A, Bhat N, Bhangoo A (2013) Bone and vitamin D metabolism in HIV. Rev Endocr Metab Disord 14(2):119\u2013125","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"812_CR143","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2249.2004.02568.x","volume":"137","author":"JM Fakruddin","year":"2004","unstructured":"Fakruddin JM, Laurence J (2004) Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis. Clin Exp Immunol 137(3):538\u2013545","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"812_CR144","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.amjmed.2008.11.027","volume":"122","author":"CJ Rosen","year":"2009","unstructured":"Rosen CJ, Klibanski A (2009) Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med 122(5):409\u2013414","journal-title":"Am J Med"},{"issue":"5","key":"812_CR145","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1310\/hct1405-224","volume":"14","author":"JS Huang","year":"2013","unstructured":"Huang JS et al (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14(5):224\u2013234","journal-title":"HIV Clin Trials"},{"issue":"6","key":"812_CR146","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/phar.1257","volume":"33","author":"JJ Schafer","year":"2013","unstructured":"Schafer JJ, Manlangit K, Squires KE (2013) Bone health and human immunodeficiency virus infection. Pharmacotherapy 33(6):665\u2013682","journal-title":"Pharmacotherapy"},{"issue":"5","key":"812_CR147","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10067-014-2627-x","volume":"35","author":"L Mateo","year":"2016","unstructured":"Mateo L et al (2016) Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol 35(5):1271\u20131279","journal-title":"Clin Rheumatol"},{"issue":"9987","key":"812_CR148","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","volume":"385","author":"PE Sax","year":"2015","unstructured":"Sax PE et al (2015) Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 385(9987):2606\u20132615","journal-title":"Lancet"},{"issue":"8","key":"812_CR149","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/infdis\/jiv194","volume":"212","author":"TT Brown","year":"2015","unstructured":"Brown TT et al (2015) Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate\/emtricitabine plus atazanavir\/ritonavir, darunavir\/ritonavir, or raltegravir. J Infect Dis 212(8):1241\u20131249","journal-title":"J Infect Dis"},{"issue":"3","key":"812_CR150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/QAD.0000000000000918","volume":"30","author":"I Ofotokun","year":"2016","unstructured":"Ofotokun I et al (2016) Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS 30(3):405\u2013414","journal-title":"AIDS"},{"issue":"4","key":"812_CR151","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/apc.2014.0205","volume":"29","author":"E Mazzotta","year":"2015","unstructured":"Mazzotta E et al (2015) Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density management. AIDS Patient Care STDS 29(4):169\u2013180","journal-title":"AIDS Patient Care STDS"},{"issue":"3","key":"812_CR152","first-page":"115","volume":"21","author":"TT Brown","year":"2013","unstructured":"Brown TT (2013) Challenges in the management of osteoporosis and vitamin D deficiency in HIV infection. Top Antivir Med 21(3):115\u2013118","journal-title":"Top Antivir Med"},{"issue":"5","key":"812_CR153","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"154","author":"Force, U.S.P.S.T.","year":"2011","unstructured":"Force, U.S.P.S.T. (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154(5):356\u2013364","journal-title":"Ann Intern Med"},{"issue":"6","key":"812_CR154","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hiv.12123","volume":"15","author":"M Bloch","year":"2014","unstructured":"Bloch M et al (2014) Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48\u00a0weeks. HIV Med 15(6):373\u2013380","journal-title":"HIV Med"},{"issue":"12","key":"812_CR155","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1093\/jac\/dku300","volume":"69","author":"E Negredo","year":"2014","unstructured":"Negredo E et al (2014) Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother 69(12):3368\u20133371","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"812_CR156","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1310\/MD8V-5DLG-EN3T-BRHX","volume":"5","author":"G Guaraldi","year":"2004","unstructured":"Guaraldi G et al (2004) Alendronate reduces bone resorption in HIV-associated osteopenia\/osteoporosis. HIV Clin Trials 5(5):269\u2013277","journal-title":"HIV Clin Trials"},{"issue":"4","key":"812_CR157","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.qai.0000145352.04440.1e","volume":"38","author":"K Mondy","year":"2005","unstructured":"Mondy K et al (2005) Alendronate, vitamin D, and calcium for the treatment of osteopenia\/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 38(4):426\u2013431","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"18","key":"812_CR158","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1097\/QAD.0b013e3282ef961d","volume":"21","author":"GA McComsey","year":"2007","unstructured":"McComsey GA et al (2007) Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 21(18):2473\u20132482","journal-title":"AIDS"},{"issue":"7","key":"812_CR159","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/hiv.12260","volume":"16","author":"E Negredo","year":"2015","unstructured":"Negredo E et al (2015) Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years. HIV Med 16(7):441\u2013448","journal-title":"HIV Med"},{"issue":"6","key":"812_CR160","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1210\/jc.2012-1424","volume":"97","author":"MJ Bolland","year":"2012","unstructured":"Bolland MJ et al (2012) Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. J Clin Endocrinol Metab 97(6):1922\u20131928","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"812_CR161","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/cid\/ciw331","volume":"63","author":"I Ofotokun","year":"2016","unstructured":"Ofotokun I et al (2016) A single-dose zoledronic acid infusion prevents antiretroviral therapy-induced bone loss in treatment-naive HIV-infected patients: a phase IIb trial. Clin Infect Dis 63(5):663\u2013671","journal-title":"Clin Infect Dis"},{"issue":"4","key":"812_CR162","first-page":"213","volume":"16","author":"MR Pinzone","year":"2014","unstructured":"Pinzone MR et al (2014) Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis. AIDS Rev 16(4):213\u2013222","journal-title":"AIDS Rev"},{"issue":"4","key":"812_CR163","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1086\/519978","volume":"45","author":"CJ Hoffmann","year":"2007","unstructured":"Hoffmann CJ, Brown TT (2007) Thyroid function abnormalities in HIV-infected patients. Clin Infect Dis 45(4):488\u2013494","journal-title":"Clin Infect Dis"},{"key":"812_CR164","first-page":"3874257","volume":"2016","author":"S Ji","year":"2016","unstructured":"Ji S et al (2016) Prevalence and influencing factors of thyroid dysfunction in HIV-infected patients. Biomed Res Int 2016:3874257","journal-title":"Biomed Res Int"},{"issue":"8","key":"812_CR165","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00002030-200005260-00026","volume":"14","author":"M Grappin","year":"2000","unstructured":"Grappin M et al (2000) Increased prevalence of subclinical hypothyroidism in HIV patients treated with highly active antiretroviral therapy. AIDS 14(8):1070\u20131072","journal-title":"AIDS"},{"issue":"5","key":"812_CR166","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00002030-200303280-00019","volume":"17","author":"J Collazos","year":"2003","unstructured":"Collazos J, Ibarra S, Mayo J (2003) Thyroid hormones in HIV-infected patients in the highly active antiretroviral therapy era: evidence of an interrelation between the thyroid axis and the immune system. AIDS 17(5):763\u2013765","journal-title":"AIDS"},{"issue":"12","key":"812_CR167","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1089\/thy.2012.0205","volume":"22","author":"JR Garber","year":"2012","unstructured":"Garber JR et al (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22(12):1200\u20131235","journal-title":"Thyroid"},{"issue":"1","key":"812_CR168","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/595006","volume":"48","author":"MA French","year":"2009","unstructured":"French MA (2009) HIV\/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 48(1):101\u2013107","journal-title":"Clin Infect Dis"},{"issue":"4","key":"812_CR169","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2265.2006.02472.x","volume":"64","author":"G Madeddu","year":"2006","unstructured":"Madeddu G et al (2006) Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. Clin Endocrinol (Oxf) 64(4):375\u2013383","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"812_CR170","first-page":"4254","volume":"85","author":"V Jubault","year":"2000","unstructured":"Jubault V et al (2000) Sequential occurrence of thyroid autoantibodies and Graves\u2019 disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 85(11):4254\u20134257","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"812_CR171","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4158\/EP.17.3.456","volume":"17","author":"RS Bahn","year":"2011","unstructured":"Bahn RS et al (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 17(3):456\u2013520","journal-title":"Endocr Pract"},{"issue":"9","key":"812_CR172","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.1984.03350090028018","volume":"252","author":"K Welch","year":"1984","unstructured":"Welch K et al (1984) Autopsy findings in the acquired immune deficiency syndrome. JAMA 252(9):1152\u20131159","journal-title":"JAMA"},{"issue":"45","key":"812_CR173","doi-asserted-by":"crossref","first-page":"35209","DOI":"10.1074\/jbc.M005197200","volume":"275","author":"BE Sawaya","year":"2000","unstructured":"Sawaya BE et al (2000) Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem 275(45):35209\u201335214","journal-title":"J Biol Chem"},{"issue":"1","key":"812_CR174","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1084\/jem.189.1.51","volume":"189","author":"T Kino","year":"1999","unstructured":"Kino T et al (1999) The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med 189(1):51\u201362","journal-title":"J Exp Med"},{"issue":"3","key":"812_CR175","first-page":"608","volume":"74","author":"G Norbiato","year":"1992","unstructured":"Norbiato G et al (1992) Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74(3):608\u2013613","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"812_CR176","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00002030-199106000-00013","volume":"5","author":"F Raffi","year":"1991","unstructured":"Raffi F et al (1991) Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 5(6):729\u2013733","journal-title":"AIDS"},{"issue":"2","key":"812_CR177","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1330173","volume":"133","author":"A Biglino","year":"1995","unstructured":"Biglino A et al (1995) Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection. Eur J Endocrinol 133(2):173\u2013179","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"812_CR178","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1530\/acta.0.1210633","volume":"121","author":"B Verges","year":"1989","unstructured":"Verges B et al (1989) Adrenal function in HIV infected patients. Acta Endocrinol (Copenh) 121(5):633\u2013637","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"5","key":"812_CR179","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/ajcp\/84.5.594","volume":"84","author":"BJ Glasgow","year":"1985","unstructured":"Glasgow BJ et al (1985) Adrenal pathology in the acquired immune deficiency syndrome. Am J Clin Pathol 84(5):594\u2013597","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"812_CR180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5588\/ijtld.13.0684","volume":"1","author":"R Baker","year":"1997","unstructured":"Baker R, Rook GA, Zumla A (1997) Adrenal function and the hypothalamo-pituitary adrenal axis in immunodeficiency virus-associated tuberculosis. Int J Tuberc Lung Dis 1(3):289\u2013290","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"812_CR181","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0732-8893(95)00249-9","volume":"24","author":"Y Arabi","year":"1996","unstructured":"Arabi Y et al (1996) Adrenal insufficiency, recurrent bacteremia, and disseminated abscesses caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome. Diagn Microbiol Infect Dis 24(1):47\u201351","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"812_CR182","first-page":"330","volume":"145","author":"LJ Schwartz","year":"1991","unstructured":"Schwartz LJ et al (1991) Endocrine function in children with human immunodeficiency virus infection. Am J Dis Child 145(3):330\u2013333","journal-title":"Am J Dis Child"},{"issue":"5","key":"812_CR183","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2214\/ajr.160.5.8470595","volume":"160","author":"DR Radin","year":"1993","unstructured":"Radin DR et al (1993) AIDS-related non-Hodgkin\u2019s lymphoma: abdominal CT findings in 112 patients. AJR Am J Roentgenol 160(5):1133\u20131139","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"812_CR184","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0190-9622(93)70057-Z","volume":"28","author":"JW Tappero","year":"1993","unstructured":"Tappero JW et al (1993) Kaposi\u2019s sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 28(3):371\u2013395","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"812_CR185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00000441-200102000-00005","volume":"321","author":"MS Eledrisi","year":"2001","unstructured":"Eledrisi MS, Verghese AC (2001) Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci 321(2):137\u2013144","journal-title":"Am J Med Sci"},{"issue":"15","key":"812_CR186","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/archinte.1997.00440360053005","volume":"157","author":"M Mann","year":"1997","unstructured":"Mann M et al (1997) Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 157(15):1651\u20131656","journal-title":"Arch Intern Med"},{"issue":"9","key":"812_CR187","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/archinte.1997.00440300118010","volume":"157","author":"S Subramanian","year":"1997","unstructured":"Subramanian S et al (1997) Clinical adrenal insufficiency in patients receiving megestrol therapy. Arch Intern Med 157(9):1008\u20131011","journal-title":"Arch Intern Med"},{"issue":"6\u20137","key":"812_CR188","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1055\/s-2007-978903","volume":"30","author":"P Putignano","year":"1998","unstructured":"Putignano P et al (1998) The effects of anti-convulsant drugs on adrenal function. Horm Metab Res 30(6\u20137):389\u2013397","journal-title":"Horm Metab Res"},{"issue":"6","key":"812_CR189","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1468-1293.2008.00579.x","volume":"9","author":"MM Foisy","year":"2008","unstructured":"Foisy MM et al (2008) Adrenal suppression and Cushing\u2019s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 9(6):389\u2013396","journal-title":"HIV Med"},{"issue":"9","key":"812_CR190","first-page":"1768","volume":"90","author":"V Prasanthai","year":"2007","unstructured":"Prasanthai V et al (2007) Prevalence of adrenal insufficiency in critically ill patients with AIDS. J Med Assoc Thai 90(9):1768\u20131774","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"812_CR191","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ecl.2014.06.002","volume":"43","author":"GP Chrousos","year":"2014","unstructured":"Chrousos GP, Zapanti ED (2014) Hypothalamic-pituitary-adrenal axis in HIV infection and disease. Endocrinol Metab Clin North Am 43(3):791\u2013806","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"812_CR192","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1210\/jcem-59-6-1204","volume":"59","author":"V Kyriazopoulou","year":"1984","unstructured":"Kyriazopoulou V, Parparousi O, Vagenakis AG (1984) Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 59(6):1204\u20131206","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"812_CR193","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.beem.2017.02.006","volume":"31","author":"V Rochira","year":"2017","unstructured":"Rochira V, Guaraldi G (2017) Growth hormone deficiency and human immunodeficiency virus. Best Pract Res Clin Endocrinol Metab 31(1):91\u2013111","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"812_CR194","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/01.aids.0000180099.35146.30","volume":"19","author":"J Falutz","year":"2005","unstructured":"Falutz J et al (2005) A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 19(12):1279\u20131287","journal-title":"AIDS"},{"issue":"4","key":"812_CR195","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jama.2014.8334","volume":"312","author":"TL Stanley","year":"2014","unstructured":"Stanley TL et al (2014) Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 312(4):380\u2013389","journal-title":"JAMA"},{"issue":"9\u201310","key":"812_CR196","first-page":"617","volume":"50","author":"S Ram","year":"2004","unstructured":"Ram S et al (2004) Serum prolactin in human immunodeficiency virus infection. Clin Lab 50(9\u201310):617\u2013620","journal-title":"Clin Lab"},{"issue":"9234","key":"812_CR197","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0140-6736(00)02697-0","volume":"356","author":"J Hutchinson","year":"2000","unstructured":"Hutchinson J et al (2000) Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet 356(9234):1003\u20131004","journal-title":"Lancet"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-017-0812-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T10:00:09Z","timestamp":1719741609000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-017-0812-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":197,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s40618-017-0812-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,8]]}}}